A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Nu 3 (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions
- Sponsors Lakewood Amedex
- 04 Dec 2017 According to a Lakewood-Amdex media release, positive top-line data from this trial will be presented at the LD MICRO Main Event.
- 29 Sep 2017 According to a Lakewood Amedex media release, the company will present top-line data at the BioPharm America Conference 2017.
- 27 Sep 2017 According to a Lakewood Amedex media release, Dr. Alexander Reyzelman is Principal Investigator of the study